Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F. Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Carrico J, Mellott C, Talbird S, Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Anderson S, Talbird SE, Fishman J, Mody-Patel N, Sarda SP. Budget impact of pegcetacoplan, a complement c3 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria in US adults. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371

Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C. Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Supplement 3):S225.

Talbird SE, Hogea CS, Meyers J, Carrico J, Buck PO. Cost-effectiveness of a 10-year revaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TDaP) vaccine among individuals with pre-existing asthma in the United States. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S153. doi: 10.1016/j.jval.2018.04.1062

Talbird SE, La EM, Mauskopf J, Krueger WS, Altland A, Daniels VJ, Pillsbury M, Wolfson LJ. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A325.

Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.

Odom D, Brogan AJ, Talbird SE, Schenkel B. A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. [abstract] Value Health. 2013 May; 16(3):A112. doi: 10.1016/j.jval.2013.03.532

Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.

Talbird SE, Bell K, Graham JB, Deal L, Mauskopf J. Cost-effectiveness analysis for treatment of symptomatic uterine fibroids among premenopausal women seeking to retain uterus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A183.

Bapat B, Davis KL, Bell K, Deal L, Talbird SE. Treatment patterns and economic burden of uterine fibroids in a United States managed care database. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 25, 2010. [abstract] Value Health. 2010 May; 13(3):A182.

Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.

Ismaila A, Pereira J, Robson R, Talbird SE, Standaert B, Rawson N. Budget-impact analysis of adding the new 10-valent pneumococcal conjugate vaccination (PHiD-CV) to routine infant vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A418.